The surge in U.S. oil production since 2008 has created tremendous opportunities for the midstream companies involved in oil storage and transportation. Many continue to invest record amounts of cash into new projects to help alleviate regional supply bottlenecks and get the crude oil to those who demand it.
But despite midstream companies' best efforts, they've lost a great deal of market share to railroads, which have rapidly emerged as their biggest competitors over the past couple of years. Let's take a look at how railroads have turned the logistics of crude oil transport on its head and what the future may hold for crude-by-rail.
The staggering growth of crude by rail
Today, the rail industry is transporting more oil than it has since the days of John D. Rockefeller's Standard Oil. In the first quarter of 2013, railways shipped a record 97,135 carloads of crude oil, according to the Association of American Railroads. That represents a 166% increase over the first quarter of 2012 and a 922% gain over crude rail shipments during the entirety of 2008.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase III clinical development as a treatment for Parkinson's disease psychosis. It is also developing AGN-XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development in collaboration with Meiji Seika Kaisha, Ltd. In addition, ACADIA Pharmaceuticals Inc. is developing two preclinical programs in the area of Parkinson?s disease. The product candidates in the company?s pipeline emanate from discoveries made using its proprietary drug discovery platform. The company was founded in 1993 and is headquartered in San Diego, California.
Advisors' Opinion: - [By Bryan Murphy]
Call them hunches (because that's all they are), but now would be a great time to get out of a NanoTech Entertainment, Inc. (OTCMKTS:NTEK) position and/or get into an ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). NTEK looks like its reached its maximum potential - for the time being - while ACAD looks like it's ready to start rolling higher again.
- [By David Williamson]
After an incredible performance in late March, when shares of Acadia Pharmaceuticals (NASDAQ: ACAD ) jumped up 23%, they have once again exploded today, up 40% intraday. What's behind these massive leaps for this pharmaceutical company, and is there more on the way? In this video, Motley Fool health-care analyst David Williamson tells investors about the drug that has Acadia investors so excited, why it has so many competitive advantages, and what investors need to watch from here.
Hot Logistics Companies To Buy Right Now: Booz Allen Hamilton Holding Corp (BAH)
Booz Allen Hamilton Holding Corporation (Booz Allen Holding), incorporated in May 2008, is a provider of management and technology consulting services to the United States government in the defense, intelligence and civil markets. In addition, it provides management and technology consulting services to corporations, institutions, and not-for-profit organizations. During the fiscal year ended March 31, 2012 (fiscal 2012), it derived 98% of its revenue from services provided to more than 1,200 client organizations across the United States government under more than 5,800 contracts and task orders. During fiscal 2012, it derived 90% of its revenue in fiscal 2012 from engagements, for which it acted as the prime contractor. On November 30, 2012, the Company purchased the Defense Systems Engineering and Support (DSES) division of ARINC Incorporated.
Defense Clients
During fiscal 2012, the Company�� defense business revenue represented 53% of its business. It works with its the United States Army clients to help sustain their land combat capabilities while responding to current demands and preparing for future needs. The services, which it provided include enhancing field intelligence systems, delivering rapid response solutions to counter improvised explosive devices, infusing lifecycle sustainment capabilities to improve distribution and delivery of material, and employing systems and consulting methods to help expand care and support for soldiers and their families. Its clients include Army Headquarters, Army Material Command (AMC), Forces Command (FORSCOM), Training and Doctrine Command (TRADOC), and Program Executive Offices, Direct Reporting Units and Army Service Component Commands.
The Company employs a multidimensional approach, which analyzes and balances people, processes, technology, and infrastructure to meet their missions of equipping global forces. Its clients include the Office of the Secretary of the Navy, Chief of Naval Operations, the Commandant ! of the Marine Corps to the Office of Naval Intelligence, and the United States Navy/Marine Corps operating commands and systems commands, as well as the Joint Program Executive Offices (PEO) and individual PEOs, such as Naval Air Systems Command (NAVAIR), Naval Seas Systems Command (NAVSEA), United States Marine Corps Systems Command, and Space and Naval Warfare (SPAWAR).
The Company provides integrated strategy and technical services to the United States Air Force. It brings capabilities to assignments, which includes weapons analysis, capability-based planning, and aircraft systems engineering. It also supports the space industry. Its clients include Air Combat Command, Air Force Space Command, Air Force Materiel Command, Air Mobility Command, Air Force Cyber Command, Air Force Pacific Command and National Aeronautics and Space Administration (NASA).
The Company provides mission-critical support to the Office of the Secretary of Defense, the Joint Staff, the Combatant Commands (COCOMs), and other the United States government departments and agencies during the planning and mission execution phases. Its clients include organizations within the Office of the Secretary of Defense and the Department of Defense�� agencies, as well as the Pacific Command, Northern Command, Central Command, the Defense Information Systems Agency (DISA), Southern Command, European Command, Strategic Command, Special Operations Command, and Transportation Command.
The Company provides solutions designed to protect infrastructure systems for the public and private sector to its United States government defense and intelligence agency clients to meet cyber warfare threats. Its cyber professionals handles the sensitive materials, assist clients in all phases of cyber-security operations and dynamic network defense. It develops cyber-security solutions utilizing a multi-dimensional approach, including people, operations, technology, policy, and management.
Intelligence Clients
The Company provides the primary group of government agencies and organizations, which carry out intelligence activities for the United States government (the United States Intelligence Community), with consulting and mission support services in analysis, systems engineering, program management, operations, organization, and change management, budget and resource management, studies, and war-gaming. During fiscal 2012, its intelligence business represented 23% of its business based on revenue. Its intelligence clients include United States Intelligence Agencies, Joint Staff and Unified Combatant Commands, and Military Intelligence.
The Company provides critical support in strategic planning, policy development, program development and execution, information sharing, architecture, and program management for research and development projects, as well as support to reform initiatives flowing from the Intelligence Reform and Terrorism Protection Act. It delivers intelligence analysis, including providing all-source intelligence analysis and open-source intelligence analysis. It also provides data collection management and analytical systems intelligence training services, and provides intellectual capital for intelligence activities. It provides consulting services, integrated intelligence and information operations mission support, and a range of counterintelligence services to the United States Army, United States Air Force, United States Navy, Marine Corps, and Defense Intelligence Agency.
Civil Clients
During fiscal 2012, the Company�� civil business represented 24% of its business based on revenue. Its civil government clients include Financial Services, Health, Energy, Transportation and Environment, Justice and Homeland Security, and Business of Government. The Company provides support to the United States government finance and treasury organizations charged with the collection, management, and protection of the United States financial system, including ! the Depar! tment of the Treasury, Internal Revenue Service, and other agencies of the Department of the Treasury, Office of the Comptroller of the Currency, Federal Deposit Insurance Corporation, Federal Reserve Board and Banks, the Securities and Exchange Commission (SEC), and Pension Benefit Guaranty Corporation. It creates approaches to challenging problems, including bank receivership, payment channel modernization, cyber initiatives, and fraud detection.
The Company supports United States government clients on projects, which helps to achieve public health missions, including entitlement reform, developing a national health information network, mitigating risk to populations, improving government infrastructure, and facilitating an international public-private sector dialogue on international health issues. Its clients include the Department of Health and Human Services and its agencies, including the United States Food and Drug Administration, National Institutes of Health, Centers for Disease Control and Prevention (CDC), the Centers for Medicare and Medicaid Services, the Department of Defense Military Health System, and Department of Veterans Affairs.
The Company supports clients in the transportation, energy, and environment sectors which controls over its national infrastructure. Its services include strategy, operations, technology, and engineering. Its clients include the Departments of Energy, Transportation, and Interior and their component agencies, and the Environmental Protection Agency. It also supports the Department of Defense in environmental and infrastructure programs in the United States and Europe. The Company supports the United States government�� homeland security mission and operations in the areas of intelligence (analysis, information sharing, and risk assessment), operations (coordination, contingency planning, and decision support), strategy, technology and management (program management and information technology tools), emergency management and respo! nse plann! ing, and border, cargo, and transportation security. It supports law enforcement missions and operations in counterterrorism, intelligence and counterintelligence, and criminal areas (narcotics, white collar crime, organized crime, and violent crime).
The Company helps agencies manage the business processes, which support government in its provision of services to its citizens, spanning management, personnel, budget operations, information technology, and telecommunications. Its clients include the General Services Administration, Office of Management and Budget, Office of Personnel Management, the Congress and Courts. It also support public sector grant-making agencies, from health and education, to labor and homeland and economic security, serving clients, such as the Departments of Agriculture, Homeland Security, Commerce, Education, Labor, and Housing and Urban Development, as well as the National Science Foundation. In addition, it serves the United States government clients abroad in helping them resolve systemic global development needs. Its clients include the United States Agency for International Development, the Department of State, Millennium Challenge Corporation, and the World Bank.
Commercial and International Clients
The Company is serving industries, such as financial services, healthcare, and energy. Its service offerings to commercial clients include dynamic defense (cyber), next-generation virtual infrastructure, decision analytics, design for affordability, and smart compliance. Its commercial clients include major commercial banks and investment banks, healthcare providers, energy companies, and utilities. Its international activities are focused on the Middle East and North Africa region. Its service offerings to international clients focuses on on-line government services and cloud applications, enterprise resource planning, advanced persistent threat resolution, supervisory control and data acquisition, and geospatial systems. Its internati! onal clie! nts include government ministries and commercial companies in the Middle East and North Africa.
The Company competes with CACI International, Inc., L-3 Communications Holdings, Inc., ManTech International Corp., SRA International, Inc., TASC Inc., General Dynamics Corp., Lockheed Martin Corp., Northrop Grumman Corp., Raytheon Co., Accenture, Computer Sciences Corp., Deloitte Consulting LLP and SAIC, Inc.
Advisors' Opinion: - [By Rich Smith]
The winners of this mega contract included:
Britain's BAE Systems (NASDAQOTH: BAESY ) Booz Allen Hamilton (NYSE: BAH ) Engility Corp. (NYSE: EGL ) and three privately held companies -- Coherent Technical Services, AM Pierce and Associates, and Sierra Nevada Corp. Each of the six will share in a cost-plus-fixed-fee multiple award contract to supply systems engineering support to the Naval Air Warfare Center Aircraft Department, Aircraft Control Systems Division. Contractors will work on such cutting-edge programs as Joint Precision Approach and Landing Systems (JPALS), Navy Unmanned Combat Aerial Systems (UCAS), Unmanned Carrier-Launched Airborne Surveillance and Strike (UCLASS), Broad Area Maritime Surveillance (BAMS), War Fighter Networking, Unmanned Aircraft System/Ground Based Sense and Avoid, and Automated Aerial Refueling Support.
- [By Rich Smith]
The Department of Defense awarded nine contracts worth a combined $239.5 million Monday. Among public companies, a few of the bigger winners included:
General Electric (NYSE: GE ) won a $45.2 million award exercising an option on a previously awarded contract. GE will supply the U.S. Navy with seven F414-GE-400 spare engines and multiple engine components for its F/A-18E/F fighter jets.�This contract should be complete by November 2015. Booz Allen Hamilton (NYSE: BAH ) is a winner in a $30.9 million award under an indefinite-delivery/indefinite-quantity (IDIQ), cost-plus-fixed-fee, multiple-award contract "for support of emerging navigation technologies for air and shipboard command, control, communications, computers, intelligence, surveillance, reconnaissance system applications."�The DoD's contract announcement said a second, unnamed contractor has won a similar award, and both awardees will now have to compete for individual task orders the Navy may put up for bid over the next three years. Additionally, this contract may be extended by a two-year option period -- potentially raising the value of the contract to $52.7 million, and potentially extending the contract out to May 5, 2016. B/E Aerospace (NASDAQ: BEAV ) was awarded an unrelated maximum $6.6 million contract. B/E will supply various engine parts, avionics, wheels, and brakes to the U.S. Army, Navy, and Air Force, as needed through May 5, 2017. link
- [By Rich Smith]
On Tuesday, the Department of Defense awarded contractor Booz Allen Hamilton (NYSE: BAH ) a contract worth an estimated $65.6 million to support the Defense Readiness Support System-Navy.
- [By Rich Smith]
The Department of Defense awarded three of its favorite defense contractors a combined $220 million on Monday, hiring each of Booz Allen Hamilton (NYSE: BAH ) , SAIC (NYSE: SAI ) , and Engility Holdings (NYSE: EGL ) to "support shore networks with sustainment services for the Base Level Information Infrastructure."
Hot Logistics Companies To Buy Right Now: Lincoln Electric Holdings Inc (LECO)
Lincoln Electric Holdings, Inc., incorporated in 1906, is a manufacturer of welding, cutting and brazing products. Welding products include arc welding power sources, wire feeding systems, robotic welding packages, fume extraction equipment, consumable electrodes and fluxes. The Company's product offering also includes computer numeric controlled (CNC) plasma and oxy-fuel cutting systems and regulators and torches used in oxy-fuel welding, cutting and brazing. The Company operates in five segments: North America Welding, Europe Welding, Asia Pacific Welding, South America Welding and The Harris Products Group. On July 29, 2011, the Company acquired Techalloy Company, Inc. and certain assets of its parent company, Central Wire Industries Ltd. On July 29, 2011, the Company acquired Applied Robotics, Inc. (doing business as Torchmate) (Torchmate). On January 31, 2011, the Company acquired SSCO Manufacturing, Inc. (doing business as Arc Products) (Arc Products). On March 11, 2011, the Company completed the acquisition of OOO Severstal-metiz: welding consumables (Severstal). In March 2012, the Company acquired Weartech International, Inc. In May 2012, the Company acquired Wayne Trail Technologies, Inc., a manufacturer of automated systems and tooling, serving a range of applications in the metal processing market. In November 2012, ITT Corp sold its shape cutting product lines, including the Burny and Kaliburn brands to the Company. In January 2013, the Company acquired Tennessee Rand, Inc.
The North America Welding segment includes welding operations in the United States, Canada and Mexico. The Europe Welding segment includes welding operations in Europe, Russia and Africa. The other two welding segments include welding operations in Asia Pacific and South America, respectively. The Harris Products Group includes the Company's global cutting, soldering and brazing businesses as well as the retail business in the United States. The arc welding power sources and wire feeding systems man! ufactured by the Company range in technology from basic units used for light manufacturing and maintenance to robotic applications for high volume production welding and fabrication. Three primary types of arc welding electrodes are produced: coated manual or stick electrodes; solid electrodes produced in coil, reel or drum forms for continuous feeding in mechanized welding, and cored electrodes produced in coil form for continuous feeding in mechanized welding.
Advisors' Opinion: - [By Seth Jayson]
Lincoln Electric Holdings (Nasdaq: LECO ) is expected to report Q2 earnings on July 29. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Lincoln Electric Holdings's revenues will expand 1.8% and EPS will expand 9.9%.
Hot Logistics Companies To Buy Right Now: Forest Laboratories Inc (FRX)
Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company�� principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor (SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.
Aclidinium
In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback system which, through a ��olored control window��and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.
Linaclotide
Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.
Viibryd
As a result of its acquisition of Clinical Data, Inc. (Clinical Data) completed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.
Daliresp
In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Namenda
Namenda (memantine HCl) is an N-methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer�� disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer�� type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.
Bystolic
Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).
Savella
Savella (milnacipran HCl) is the Company�� selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.
Teflaro
In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.
Avibactam
Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.
Lexapro
Lexapro�� is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro�� (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.
Cariprazine
Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also undergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.
Levomilnacipran
Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.
GRT 6005
In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.
TTP399
In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.
Azimilide
In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA agreed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.
RGH-618
RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.
Advisors' Opinion: - [By Ben Levisohn]
The S&P 500 is getting a boost today from Alcoa (AA), which has gained 4.1% to $8.95 after it announced a joint venture aimed at the aerospace industry, Forest Labs (FRX), which has climbed 3.8% to $56.01 after reporting better-than-forecast earnings and guidance and Freeport-McMoran Copper & Gold (FCX), which reported better-than-expected earnings and said it would seek significant cost cuts.
- [By Lauren Pollock var popups = dojo.query(".socialByline .popC"); popups.forEach]
Forest Laboratories Inc.(FRX) agreed to acquire Furiex Pharmaceuticals(FURX) in a deal worth up to $1.33 billion that expands Forest Labs’ presence in gastroenterology. Furiex surged 28% to $102.21 premarket.
- [By Keith Speights]
A bigger factor in the loss, though, was that sales and admin costs more than doubled during the first quarter. Ironwood and its partner Forest Labs (NYSE: FRX ) launched chronic constipation drug Linzess in December. Sales for the drug since its introduction to the market total around $24 million. Forest Labs says it expects Linzess to rack up $170 million in sales by the end of Q1 2014.
Hot Logistics Companies To Buy Right Now: Rvue Holdings Inc (RVUE)
rVue Holdings, Inc., incorporated on November 12, 2008, is an advertising technology company and operate rVue, a demand-side platform (DSP) for planning, buying and managing digital place-based networks and digital billboards and signage (DOOH) advertising. It provides media services, including an online, Internet based DSP that connects advertisers and/or advertising agencies with third party DOOH media or networks, that allows the advertiser to create a targeted advertising campaign and media plan, and negotiate that media plan simultaneously with all the third-party networks selected. The Company provides network services and receive fees under contract or on a monthly basis, from Accenture.
The Company's rVue DSP is accessible via the Internet. Through rVue, once an advertising campaign has been agreed to between the advertiser and the DOOH network owner, the DOOH networks receive the display advertising to be shown on their installed base of digital media displays. rVue allows programming and advertising to be customized for display in specific venues, at specific times, and for demographic targeting. It provides the tools for advertisers and advertising agencies to customize campaigns for details as specific as location, customer preference, product availability, current events and other needs. It provides Proof-of-Play analytics and the network statistics necessary to monitor advertising on the networks and assist in evaluating the performance or refinements required for an advertising campaign, in some cases real time. As of December 31, 2012, 182 networks, which consists approximately 770,000 screens and delivering over 250 million daily impressions representing 50 market areas accessible through rVue.
In connection with the Transaction, the Company acquired from Argo all of its assets related to the rVue business, which included all of the common stock of rVue, Inc. as well as software, contracts and technology. Such software and technology included the rVue DSP t! echnology and software as well as legacy rVue client and server software, which allows an end user to manage and operate a DOOH network. The client software is used to manage each screen or site and the server software is used to manage the client software. The Company�� services provide a digital advertising solution that streamlines the process of planning, buying and optimizing display advertising on DOOH display networks. rVue is designed to simplify the process of buying and selling digital display ads while connecting all the market players networks, advertisers, agencies, partners and developers from a unified platform to do business more efficiently and effectively.
Advisors' Opinion: - [By CRWE]
Today, RVUE has shed (-0.25%)�0.000 at $.199 with�5,000 shares in play thus far (ref. google finance Delayed: 9:39AM EDT July 17, 2013), but don�� let this get you down.
rVue Holdings, Inc. previously reported its financial results for the full year ended December 31, 2012.
Summary Results for the Full Year of 2012: Total revenue was $602,363 for fiscal 2012; down slightly from $643,483 in the prior year. Core Fees: This is the focus of our business and source of future growth. Core revenue for the years ended December 31, 2012 and 2011 were, $197,444 and $203,276, respectively.
Non-Core Fees: For the years ended December 31, 2012 and 2011 were $404,919 and $440,207, respectively. The decline was due to the end of a management relationship with Auto Nation. This trend will continue in 2013 as we focus more resources on core business efforts. In addition the Mattress Firm merged with Mattress Giant and we respectfully agree not to renew for 2013 (this represented approximately $230,000 in revenue).
- [By CRWE]
Today, RVUE remains (0.00%) +0.000 at $.14 thus far (ref. google finance Delayed: 11:58AM EDT August 28, 2013).
rVue Holdings, Inc. previously reported its financial results for the quarter ended March, 31 2013.
Summary Results for First Quarter of 2013: Total revenue was $137.5K for the first fiscal quarter of 2013; up slightly from $131.5K the prior year.
Core Revenue: This is the focus of our business and source of future growth. Core revenue for the quarter ended March 31, 2013 was $79.3K up sharply (+63K) over Q1 2012 when it was $16.3K. Non-Core Revenue: For the quarters ended March 31, 2013 and 2012 were $58.2K and $115.2K, respectively. As stated earlier, the decline was due to the end of a management relationship with Auto Nation. This downward trend in non-core revenue is expected to continue through 2013 as we focus more resources on core business efforts. In addition, the Mattress Firm merged with Mattress Giant and we respectfully agreed not to renew for 2013.
Hot Logistics Companies To Buy Right Now: CTC Media Inc.(CTCM)
CTC Media, Inc., together with its subsidiaries, operates as an independent media company. It operates the CTC, Domashny, and Peretz television networks in Russia. The company also operates Channel 31, a television network in Kazakhstan, as well as a television channel in Moldova offering entertainment programming. In addition, it is involved in in-house production operations that focus on series, sitcoms, and shows. CTC Media, Inc. was founded in 1989 and is headquartered in Moscow, the Russian Federation.
Advisors' Opinion: - [By James Brumley]
If they want in, it might be a lead worth following.
CTC Media (CTCM) CTCM Dividend Yield: 8.2%
When tensions between Russia and Ukraine first began to develop in early March, most Russian stocks tanked. Russian broadcast television company CTC Media (CTCM) was no exception, with its stock losing 19% of its value in March alone, on top of the 24% dip that had whacked CTCM stock from the beginning of the year through the end of March.
Hot Logistics Companies To Buy Right Now: Protalix Biotherapeutics Inc (PLX)
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.
Taliglucerase Alfa
Taliglucerase alfa is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. The Company has commenced pre-clinical studies of an oral form of taliglucerase alfa. Its oral taliglucerase alfa is a plant cell expressed form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the GCD enzyme. Pre-clinical studies of oral taliglucerase alfa demonstrate the stability of the enzyme in the cell and the capacity of the cell�� cellulose wall to protect the enzyme against degradation in the digestive tract in an in-vitro model of the stomach and intestines. Additionally, rats fed with lyophilized carrot cells expressing GCD have accumulated the active enzyme in the target organs; the spleen and liver. As of December 31, 2010, the Company had completed Phase III Clinical Trial.
PRX-102
The Company is developing PRX-102, its plant cell expressed modified version of the recombinant ! alpha-GAL-A protein, a therapeutic enzyme for the treatment of Fabry disease. Fabry disease is a rare, hereditary, genetic lysosomal storage disorder in humans caused by an X-lined deficiency of the alpha-GAL-A enzyme. The Company is in the animal evaluation testing phase of the development of PRX-102, which tests are based on a mouse model for Fabry disease.
Acetylcholinesterase
Protalix Ltd. is a wholly owned subsidiary of the Company is licensed the rights to certain technology under a research and license agreement with Yissum Research and Development Company (Yissum) and the Boyce Thompson Institute, Inc. Pursuant to the agreement, the Company is developing PRX-105, a plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, as well as in a biodefense program and an organophosphate-based pesticide treatment program.
As of December 31, 2010, its in-vitro experiments of PRX-105 have shown that the acetylcholinesterase enzyme in its ProCellEx protein expression system demonstrates biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase expressed in its ProCellEx protein expression system was able to treat animals exposed to the nerve gas agent analogues, both when injected with its acetylcholinesterase product candidate immediately before exposure or when injected after exposure. In March 2010, it initiated a preliminary phase I clinical trial of PRX-105, which the Company completed in June 2010.
pr-antiTNF
pr-antiTNF is a candidate for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis. The Company has designed the antiTNF as pr-antiTNF. pr-antiTNF is a plant cell-expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), f! used to t! he Fc component of a human antibody domain. pr-antiTNF has an identical amino acid sequence to Enbrel and its in-vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner.
The Company competes with Genzyme, Actelion, Crucell N.V., Biolex, Inc., Chlorogen, Inc., Greenovation Biotech GmbH, Symbiosys, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.
Advisors' Opinion: - [By Maxx Chatsko]
Industrial biotech isn't the only industry headed to Brazil. Protalix (NYSEMKT: PLX ) entered into a technology transfer agreement with Brazil's Ministry of Health last week that will pay the company $280 million. The deal is big news for Protalix's first product, Elelyso/Uplyso, which was developed with partner Pfizer (NYSE: PFE ) . The treatment is approved as an enzyme replacement therapy, or ERT, for adults with type 1 Gaucher disease, and it marks a huge step forward for the future of biomanufacturing. In the following video, Fool contributor Maxx Chatsko explains what this means for the product's commercialization and the adoption of Protalix's novel plant cell-based expression system for therapeutic proteins.
- [By Keith Speights]
Other investors might wish that Pfizer would use some of its cash to acquire a few smaller companies. Protalix BioTherapeutics (NYSEMKT: PLX ) has been mentioned as one possible candidate. The two companies already partner together on Gaucher disease drug Elelyso. In February, Protalix spurred rumors that Pfizer could be interested in buying the company after it announced that it had engaged Citigroup to pursue a "broad array of strategic alternatives."
